Thyroid gland carcinoma

This phase 2 trial tests whether the targeted drug trametinib can help radioactive iodine (I-131) work better in people with advanced thyroid cancer that has returned or spread. The study includes 34 participants whose cancer no longer responds to standard radioactive iodine trea…

This phase 2 trial tests whether combining lenvatinib (a targeted drug that blocks cancer growth) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can improve outcomes for people with advanced anaplastic thyroid cancer that cannot be surgically rem…

This phase II trial tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in 11 patients with advanced thyroid cancer that no longer responds to radioactive iodine or prior targeted therapy. The goal is to see if this mix can shrink tumors or stop them from g…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with anaplastic or poorly differentiated thyroid cancer live longer. About 50 patients with advanced or inoperable cancer are receiving different drug combinations…

This phase 2 trial tests whether combining two oral drugs—sorafenib and everolimus—can shrink tumors or slow disease in people with advanced thyroid cancer that cannot be removed by surgery. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps…

This study monitors 453 patients with advanced thyroid cancer that cannot be removed by surgery and does not respond to radioactive iodine. All patients are taking the drug sorafenib (Nexavar) as part of their normal care. Researchers are tracking side effects and how long patien…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This phase 2 trial tests whether giving selpercatinib before standard surgery can shrink tumors in people with RET-altered thyroid cancer. About 30 participants with advanced or recurrent disease will receive the drug and then undergo surgery. The goal is to see if the drug impro…

This early-phase trial tested a combination of two targeted drugs, dabrafenib and lapatinib, in 23 people with advanced thyroid cancer that had a specific BRAF mutation and could not be removed by surgery. The main goal was to find the safest dose of lapatinib when given with dab…

This study tests whether combining two treatments—thermal ablation (using heat to destroy tumor cells) and stereotactic radiosurgery (precise, high-dose radiation)—can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with vari…

This study tests whether two targeted drugs (encorafenib and binimetinib) with or without an immunotherapy drug (nivolumab) can shrink or slow advanced thyroid cancer that has spread and no longer responds to standard radioactive iodine treatment. About 24 adults with a specific …

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …